1. <div id="8sgz1"><ol id="8sgz1"></ol></div>

        <em id="8sgz1"><label id="8sgz1"></label></em>
      2. <em id="8sgz1"><label id="8sgz1"></label></em>
        <em id="8sgz1"></em>
        <div id="8sgz1"><ol id="8sgz1"><mark id="8sgz1"></mark></ol></div>

        <button id="8sgz1"></button>
        west china medical publishers
        Author
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Author "ZENG Yong." 2 results
        • Perioperative Assistant Therapy of Liver Transplantation for Primary Hepatocellular Carcinoma

          【Abstract】ObjectiveTo analyse the current situation and advance in perioperative therapy of liver transplantation for primary hepatocellular carcinoma(HCC).MethodsThe published papers on current situation and advance in the perioperative therapy of liver transplantation for HCC were reviewed.ResultsThe survival rate of liver transplantation for HCC in early stage has been the same as that for benign liver diseases up to now. However, it is still a difficult problem to improve the survival rate of liver transplantation for advanced HCC. The ideal perioperative therapies of liver transplantation for HCC should be helpful to suppress the growth of tumor while the HCC patients are waiting for donated livers, to diminish or eliminate the intraoperative spread or implantation of tumor cells and to repress the micrometastasis postoperatively. The current perioperative therapies of liver transplantation for HCC include hepatic arterial chemoembolization, systemic chemotherapy, radiotherapy, percutaneous ethanol injection into HCC and radiofrequency ablation etc. ConclusionThe perioperative assistant therapy of HCC can not only save time for patients before liver transplantation but also improve the survival rate after operation.

          Release date:2016-09-08 11:53 Export PDF Favorites Scan
        • The Evaluation of Surgical Treatments for Hilar Cholangiocarcinoma

          目的 對肝門膽管癌外科治療療效進行評價。 方法 回顧分析2007年3月-2012年3月收治的156例肝門膽管癌患者的臨床資料。按手術方式將患者分為手術切除組(n=45)、膽道引流組(n=78)和姑息治療組(n=33),并對住院期間并發癥發生率、病死率及生存時間等進行分析。 結果 156例患者根治性切率為23.1%不同治療方式住院期間病死率差異無統計學意義(P<0.05);手術治療組與姑息治療組并發癥發生率差異有統計學意義(P<0.05)。手術切除組、膽道引流組、姑息治療組的1、3、5年累積生存率分別為64.4%、17.8%、0.0%;40.2%、12.6%、12.6%;17.7%、7.1%、0.0%,手術切除組生存情況明顯好于其他兩組(P<0.05)。 結論 不建議所有患者術前均引流可減黃,且可以不過分強調R0切除。膽道引流可一定程度改善預后,但近遠期膽道感染相關并發癥發生率較高。

          Release date:2016-09-07 02:38 Export PDF Favorites Scan
        1 pages Previous 1 Next

        Format

        Content

          1. <div id="8sgz1"><ol id="8sgz1"></ol></div>

            <em id="8sgz1"><label id="8sgz1"></label></em>
          2. <em id="8sgz1"><label id="8sgz1"></label></em>
            <em id="8sgz1"></em>
            <div id="8sgz1"><ol id="8sgz1"><mark id="8sgz1"></mark></ol></div>

            <button id="8sgz1"></button>
            欧美人与性动交α欧美精品